VXRT - Vaxart, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2450
+0.0250 (+2.05%)
As of 03:39PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.2200
Open1.2000
Bid1.2400 x 1400
Ask1.2500 x 1800
Day's Range1.1900 - 1.2700
52 Week Range0.5600 - 4.6200
Volume1,032,945
Avg. Volume1,559,268
Market Cap168.775M
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.8200
Earnings DateAug 07, 2023 - Aug 11, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 09, 2012
1y Target Est6.13
  • GlobeNewswire

    Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET

    SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to ask questions of Company management. The first event will be a fireside chat with Vaxart executives on Thursday, June 15 at 11 a.m. ET. “Investor support is the lifeblood of a developing biotechnology company, and we are excited to further the ongoing dialogue with our shareholders,” said Andrei Floroiu

  • Simply Wall St.

    Here's Why We're A Bit Worried About Vaxart's (NASDAQ:VXRT) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • GlobeNewswire

    Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results

    On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced its business update and financial results for the first quarter of 2023. “During the first quarter, we continued to advance our norovirus oral pill vaccine program and remain on track to report two import

  • GlobeNewswire

    Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

    Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDa

  • Motley Fool

    These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge

    Right now, Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) are in this situation. Both were favorites in the early days of the coronavirus vaccine race. Novavax shares soared more than 2,700% back in 2020.

  • GlobeNewswire

    Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

    SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washington, D.C. on Wednesday, April 5 and Thursday, April 6, 2023. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination Speaker:

  • GlobeNewswire

    Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

    Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host a key opinion leader video webcast on the health and economic impact and disease burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET. The webcast will feature presentations by prominent norovirus disease experts Jan Vinjé, Ph.D., Head, Natio

  • GlobeNewswire

    Vaxart Provides Business Update and Full Year 2022 Financial Results

    Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance cross-reactivity and potency with the goal of developing a pan-betacoronavirus vaccine Portfolio prioritization extends cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today

  • GlobeNewswire

    Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

    Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March 15, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click her

  • GlobeNewswire

    Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

    Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in the Phase 2 clinical trial of its oral tablet bivalent norovirus candidate. The dose-ranging study is designed to identify a vaccine dose for a potential Phase 3 clinical trial. “Initiating the Phase 2 clinical trial of this candidate is an important achievement tow

  • Zacks

    Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?

    Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • GlobeNewswire

    Vaxart Names Phillip Lee as Chief Financial Officer

    Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today that it has appointed Phillip Lee as its Chief Financial Officer (CFO), effective immediately. “We are excited to have a CFO with Phillip’s experience in corporate finance and strategy join our team,” said Andrei Floroiu, Vaxart’s Chief Executive Officer. “He arrives at an i

  • GlobeNewswire

    Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

    Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will commence a new study of Vaxart’s oral pill norovirus vaccine candidate focused on protecting breastfeeding mothers and their infants. The study will receive significant funding

  • GlobeNewswire

    Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

    SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET. Dr. Tucker will provide an overview of Vaxart’s Phase II trial for its oral pill COVID-19 vaccine candidate. Vaxart recently announced positive top-line Phase II clinical study result

  • Simply Wall St.

    Vaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

    Vaxart ( NASDAQ:VXRT ) Third Quarter 2022 Results Key Financial Results Net loss: US$29.3m (loss widened by 67% from 3Q...

  • Zacks

    VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates

    VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

    Growing body of clinical evidence supports transformational potential of Vaxart’s oral vaccine platform Clinical trial programs on track for reporting key data milestones Ended third quarter with $114.8 million in cash, cash equivalents and marketable securities Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the third quarter of 2022, during which the Company made significant pr

  • Zacks

    VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Motley Fool

    3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street

    Wall Street has taken investors on quite the ride in 2022. In other words, buying during the dips makes a lot of sense -- and Wall Street analysts know it. Most price targets placed on publicly traded companies by Wall Street reflect this long-term optimism.

  • GlobeNewswire

    Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

    Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click

  • GlobeNewswire

    Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

    SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022. Presentation Information: Title: Long-lasting nasal mucosal responses in humans to SARS-CoV-2 following oral tablet vaccine administration of non-replicating ad

  • Motley Fool

    2 Struggling Stocks to Avoid Right Now

    Many companies will rebound from the ongoing downturn as the economy improves, but in all likelihood, many others will continue to struggle. Many rushed to invest in companies such as Canopy Growth, which has long been considered one of the leaders in the field. Cannabis companies had trouble raising funds due to the nature of their business activities.

  • GlobeNewswire

    Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. The pre-recorded presentation will be available on the Company’s Events page, accessible here: https:

  • GlobeNewswire

    Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

    — Study met primary safety and secondary immunogenicity endpoints — — Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects — — Elicited cross-reactive mucosal responses in approximately 50% of subjects — — Company to host conference call at 8:30 a.m. ET today — SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan

  • GlobeNewswire

    Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

    SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022. The Vaxart senior management team will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on the same date to review the data and provide a trial update. Analysts and investors can part